bullish
Upstream Bio IPO Preview: Severe Asthma/CRSwNP Program Advancing
227 Views25 Sep 2024 03:23
Upstream Bio, a clinical-stage biotech company focused on severe asthma, CRSwNP, COPD, filed for US IPO. Their ex-Astellas monoclonal antibody, verekitug, is currently conducting Ph. 2 clinical trials
What is covered in the Full Insight:
- Company Background
- IPO Details
- Lead Compound and Market Potential
- Competitive Landscape
- Investment Risks and Financials
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Top Quartile
Andrei Zakharov
Covering IPOs, Healthcare and Technology Stocks
Price Chart(Sign Up to Access)
- Upstream Bio IPO Preview: Severe Asthma/CRSwNP Program Advancing25 Sep 2024
x